RudaCure has been selected for the 科学技术信息通信部's 2021 Bio iCORE Project and will receive support for the next three years.
The Bio iCORE project is a program that helps domestic 生物风投企业s expand overseas. Through incubation, management, and administrative support from the Bio iCORE project team, as well as specialized education, mentoring, and consulting provided by dedicated overseas organizations, the program assists in establishing overseas subsidiaries and ultimately aims to create overseas funds. In this selection round, 5 global 初创企业 teams were chosen from among 12 pre-初创企业 teams that completed domestic training, with a total of KRW 700 million in support over three years to promote overseas grant applications.
During the project evaluation, the company was highly recognized for its strategy for overseas market entry, the completed domestic licensing agreement, high prior research leading to a predicted high success rate, excellent capabilities in the 新药开发 process, and a very specific plan for overseas expansion strategy.
RudaCure plans to use this support to build upon its domestic licensing contract with 翰林制药 and further accelerate its 全球拓展.